Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-05 03:23 | 2026-02-02 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | SELL | $25.05 | 10,000 | $250,483 | 59,744 |
| 2026-02-05 03:21 | 2026-02-02 | ARQT | Arcutis Biotherapeutics Inc. | Edwards Larry Todd | Officer | SELL | $25.50 | 2,052 | $52,323 | 148,865 |
| 2026-02-05 00:30 | 2026-02-02 | ABEO | Abeona Therapeutics Inc. | Silverstein Christine Berni | Director | SELL | $5.09 | 20,070 | $102,168 | 137,722 |
| 2026-02-05 05:15 | 2026-02-02 | MPLT | MapLight Therapeutics, Inc. | Malenka Robert C. | Director | SELL | $18.02 | 7,040 | $126,861 | 358,233 |
| 2026-02-05 03:30 | 2026-02-02 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | SELL | $25.72 | 13,469 | $346,455 | 80,651 |
| 2026-02-05 04:27 | 2026-02-02 | ZNTL | Zentalis Pharmaceuticals, Inc. | Vultaggio Vincent | Officer | SELL | $2.54 | 3,096 | $7,875 | 186,730 |
| 2026-02-05 05:44 | 2026-02-02 | SPRO | Spero Therapeutics, Inc. | Rajavelu Esther | Officer | SELL | $2.20 | 18,442 | $40,572 | 1,100,008 |
| 2026-02-05 03:37 | 2026-02-03 | URGN | UroGen Pharma Ltd. | Schoenberg Mark | Officer | SELL | $19.69 | 7,373 | $145,174 | 144,985 |
| 2026-02-05 00:05 | 2026-02-02 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Cohen Joshua B | Director, Officer | SELL | $14.68 | 15,500 | $227,593 | 3,363,965 |
| 2026-02-05 00:05 | 2026-02-02 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Mazzariello Gina | Officer | SELL | $14.65 | 3,448 | $50,516 | 144,693 |
| 2026-02-05 00:05 | 2026-02-02 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Klee Justin B. | Director, Officer | SELL | $14.69 | 15,500 | $227,618 | 3,363,898 |
| 2026-02-05 00:32 | 2025-12-05 | BOLT | Bolt Biotherapeutics, Inc. | Quinn William P. | Director, Officer | BUY | $4.61 | 125 | $576 | 2,313 |
| 2026-02-05 00:32 | 2025-12-05 | BOLT | Bolt Biotherapeutics, Inc. | Nemec Sarah | Officer | BUY | $4.61 | 125 | $576 | 1,415 |
| 2026-02-05 05:33 | 2026-02-02 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer | SELL | $32.80 | 15,000 | $492,045 | 657,540 |
| 2026-02-05 00:05 | 2026-02-02 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $58.00 | 100 | $5,800 | 450,944 |
| 2026-02-05 00:25 | 2026-02-03 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Smethurst Dominic | Officer | SELL | $8.09 | 3,285 | $26,575 | 95,887 |
| 2026-02-05 00:24 | 2026-02-03 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Hodgson Ian | Officer | SELL | $8.09 | 2,415 | $19,537 | 51,927 |
| 2026-02-05 00:10 | 2026-02-02 | FULC | Fulcrum Therapeutics, Inc. | Gould Robert J | Director | SELL | $10.72 | 15,000 | $160,857 | 454,864 |
| 2026-02-05 00:15 | 2026-01-02 | FULC | Fulcrum Therapeutics, Inc. | Gould Robert J | Director | SELL | $10.87 | 15,000 | $163,089 | 469,864 |
| 2026-02-05 00:12 | 2026-02-02 | AKBA | Akebia Therapeutics Inc. | Rucci Carolyn M. | Officer | SELL | $1.39 | 69,772 | $96,983 | 588,378 |
| 2026-02-05 00:15 | 2026-02-02 | AKBA | Akebia Therapeutics Inc. | Malabre Richard C | Officer | SELL | $1.39 | 49,524 | $68,838 | 299,390 |
| 2026-02-05 00:11 | 2026-02-02 | AKBA | Akebia Therapeutics Inc. | Ostrowski Erik | Officer | SELL | $1.39 | 34,951 | $48,582 | 672,635 |
| 2026-02-05 00:13 | 2026-02-02 | AKBA | Akebia Therapeutics Inc. | Grund Nicholas | Officer | SELL | $1.39 | 84,829 | $117,912 | 561,750 |
| 2026-02-05 00:13 | 2026-02-02 | AKBA | Akebia Therapeutics Inc. | Burke Steven Keith | Officer | SELL | $1.39 | 67,658 | $94,045 | 948,432 |
| 2026-02-05 00:10 | 2026-02-02 | AKBA | Akebia Therapeutics Inc. | Butler John P. | Director, Officer | SELL | $1.39 | 341,305 | $474,414 | 3,297,794 |
| 2026-02-05 04:12 | 2026-02-03 | TNGX | Tango Therapeutics, Inc. | Beckman Daniella | Officer | SELL | $12.26 | 10,317 | $126,531 | 184,297 |
| 2026-02-05 00:11 | 2026-02-03 | KPTI | Karyopharm Therapeutics Inc. | Macomber Lori | Officer | SELL | $6.30 | 1,626 | $10,244 | 85,105 |
| 2026-02-05 00:27 | 2026-02-03 | ZVRA | ZEVRA THERAPEUTICS, INC. | Schafer Joshua | Officer | SELL | $9.19 | 10,500 | $96,500 | 62,278 |
| 2026-02-05 00:27 | 2026-02-03 | ZVRA | ZEVRA THERAPEUTICS, INC. | Sangiovanni Timothy J. | Officer | SELL | $9.18 | 3,000 | $27,548 | 29,590 |
| 2026-02-05 04:23 | 2026-02-02 | OCUL | OCULAR THERAPEUTIX, INC | Notman Donald | Officer | SELL | $8.82 | 11,490 | $101,398 | 377,802 |
| 2026-02-05 02:24 | 2026-02-02 | KNSA | Kiniksa Pharmaceuticals International, plc | Quart Barry D | Director | OPT+S | $45.22 | 15,960 | $721,635 | 12,546 |
| 2026-02-05 03:43 | 2026-02-02 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Director | SELL | $44.58 | 30,953 | $1,379,866 | 3,530,702 |
| 2026-02-05 00:15 | 2026-02-02 | ALXO | Alx Oncology Holdings Inc. | GOODMAN COREY S | Director, 10% owner | BUY | $1.57 | 3,184,713 | $4,999,999 | 8,453,038 |
| 2026-02-05 00:05 | 2026-02-02 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | FRATES JAMES M | Officer | SELL | $14.65 | 3,557 | $52,097 | 173,547 |
| 2026-02-05 01:18 | 2026-02-02 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | SELL | $195.91 | 467 | $91,490 | 43,187 |
| 2026-02-05 00:15 | 2026-02-03 | INSM | INSMED Inc | Smith Michael Alexander | Officer | SELL | $156.27 | 640 | $100,013 | 56,397 |
| 2026-02-05 00:15 | 2026-02-02 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | OPT+S | $154.70 | 8,777 | $1,357,796 | 84,112 |
| 2026-02-05 00:20 | 2026-02-03 | INSM | INSMED Inc | Adsett Roger | Officer | SELL | $156.17 | 791 | $123,530 | 106,810 |
| 2026-02-05 00:19 | 2026-02-03 | INSM | INSMED Inc | Bonstein Sara | Officer | SELL | $156.34 | 748 | $116,942 | 79,758 |
| 2026-02-05 00:17 | 2026-02-03 | INSM | INSMED Inc | Lewis William | Director, Officer | SELL | $156.34 | 3,009 | $470,427 | 303,882 |
| 2026-02-05 00:06 | 2026-02-02 | IONS | IONIS PHARMACEUTICALS INC | BENNETT C FRANK | Officer | OPT+S | $82.93 | 85,089 | $7,056,218 | 80,293 |
| 2026-02-05 03:39 | 2026-02-02 | SION | Sionna Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director | SELL | $44.58 | 30,953 | $1,379,866 | 3,530,702 |
| 2026-02-05 00:25 | 2026-02-02 | LXRX | LEXICON PHARMACEUTICALS, INC. | Invus Global Management, LLC | Director, 10% owner | BUY | $1.30 | 1,538,462 | $2,000,001 | 1,538,462 |
| 2026-02-04 02:59 | 2026-01-30 | CNTA | Centessa Pharmaceuticals plc | HUSSAIN IQBAL J | Officer | SELL | $25.15 | 39,961 | $1,004,919 | 57,645 |
| 2026-02-04 05:45 | 2026-02-02 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | Officer | OPT+S | $103.30 | 968 | $99,998 | 4,503 |
| 2026-02-04 05:45 | 2026-02-02 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Officer | SELL | $103.30 | 2,631 | $271,792 | 20,655 |
| 2026-02-04 05:45 | 2026-02-02 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | Director, Officer | SELL | $103.30 | 9,108 | $940,888 | 160,294 |
| 2026-02-03 20:00 | 2026-02-02 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | Officer | SELL | $23.56 | 3,061 | $72,117 | 88,935 |
| 2026-02-04 00:05 | 2025-12-10 | AVBP | ArriVent BioPharma, Inc. | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10% owner | SELL | $23.37 | 555,555 | $12,983,320 | 3,929,117 |
| 2026-02-04 05:30 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | Officer | SELL | $32.12 | 7,242 | $232,613 | 112,971 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.